dc.contributor.author | Lorimer, C | |
dc.contributor.author | Cheng, L | |
dc.contributor.author | Chandler, R | |
dc.contributor.author | Garcez, K | |
dc.contributor.author | Gill, V | |
dc.contributor.author | Graham, K | |
dc.contributor.author | Grant, W | |
dc.contributor.author | Sardo Infirri, S | |
dc.contributor.author | Wadsley, J | |
dc.contributor.author | Wall, L | |
dc.contributor.author | Webber, N | |
dc.contributor.author | Wong, KH | |
dc.contributor.author | Newbold, K | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-12-20T10:18:12Z | |
dc.date.available | 2022-12-20T10:18:12Z | |
dc.date.issued | 2022-11-12 | |
dc.identifier | S0936-6555(22)00512-X | |
dc.identifier.citation | Clinical Oncology, 2022, pp. S0936-6555(22)00512-X - | |
dc.identifier.issn | 0936-6555 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5609 | |
dc.identifier.eissn | 1433-2981 | |
dc.identifier.eissn | 1433-2981 | |
dc.identifier.doi | 10.1016/j.clon.2022.10.017 | |
dc.description.abstract | AIMS: Anaplastic thyroid cancer (ATC) is a rare but aggressive form of thyroid cancer with a median survival of 4 months. Recent advances in molecular profiling have shown that up to half of ATCs harbour the BRAF-V600E mutation. The aim of this study was to provide real-world data and experience on the use of combination therapy dabrafenib and trametinib in patients with BRAF-V600E-mutated advanced ATC. MATERIALS AND METHODS: We retrospectively evaluated patients with confirmed BRAF-V600E-mutated ATC, defined as patients with locally advanced or metastatic ATC with no locoregional, radical treatment options. Outcomes measured were overall survival, progression-free survival, response rate, discontinuation rate, dose reduction rate and toxicity data. RESULTS: Seventeen patients were evaluated and the mean age was 68 years. Ten patients died by the time of censoring. The median duration of follow-up was 12 months (3-43 months). The estimated median overall survival was 6.9 months (95% confidence interval 2.46 months - upper confidence interval not reached) and the median progression-free survival was 4.7 months (95% confidence interval 1.4-7.8 months). Dose interruptions and/or reductions were common, but none of the patients had to permanently discontinue treatment because of toxicities. Severe toxicities (grades 3 and 4) were uncommon. CONCLUSIONS: This study supports the indication of dabrafenib and trametinib in BRAF-V600E-mutated ATC as an effective and well-tolerated treatment in an historically difficult to treat cancer. | |
dc.format | Print-Electronic | |
dc.format.extent | S0936-6555(22)00512-X - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE LONDON | |
dc.relation.ispartof | Clinical Oncology | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | BRAF mutation | |
dc.subject | anaplastic thyroid cancer | |
dc.subject | dabrafenib | |
dc.subject | trametinib | |
dc.title | Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-10-25 | |
dc.date.updated | 2022-12-14T11:58:37Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.clon.2022.10.017 | |
rioxxterms.licenseref.startdate | 2022-11-12 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36379836 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/22/23 Starting Cohort | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.clon.2022.10.017 | |
icr.researchteam | Targeted Therapy | |
dc.contributor.icrauthor | Cheng, Leslie | |
icr.provenance | Deposited by Dr Leslie Cheng on 2022-12-14. Deposit type is initial. No. of files: 1. Files: s41467-017-00965-y.pdf | |